Phillip Camp, MD
Cardiovascular Disease · Albuquerque, NMNPI 1710229638
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Pfizer at 56.3% of the total. Among cardiovascular disease clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $105.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Abbott$2K
- Boston Scientific$797
- Abiomed$554
- AstraZeneca$329
- Heartflow, Inc.$315
- plus $749 from 11 others
What the payments were for
- Speaking & faculty fees$5,02547%
- Travel & lodging$2,89527%
- Food & beverage$2,74526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $6,004 |
| Abbott | 11 | $1,918 |
| Boston Scientific | 28 | $797 |
| Abiomed | 2 | $554 |
| AstraZeneca | 9 | $329 |
| Heartflow, Inc. | 4 | $315 |
| Novartis | 9 | $177 |
| E.r. Squibb & Sons, L.L.C. | 8 | $168 |
| Medtronic | 1 | $88 |
| Amgen | 4 | $76 |
| Cleerly, Inc. | 1 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $62 |
| Boehringer Ingelheim | 1 | $46 |
| Chiesi USA, Inc. | 1 | $20 |
| Atricure, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,665 in reported general payments places this provider in the 90th percentile of 101 cardiovascular disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndaqelTafamidis Meglumine | 13 | $303,898 |
| XareltoRivaroxaban | 139 | $175,708 |
| EntrestoSacubitril/Valsartan | 71 | $100,591 |
| EliquisApixaban | 64 | $82,178 |
| FarxigaDapagliflozin Propanediol | 24 | $26,725 |
| BrilintaTicagrelor | 12 | $8,281 |
| Repatha SureclickEvolocumab | 11 | $8,003 |
| Bumetanide | 113 | $3,497 |
| Atorvastatin Calcium | 218 | $3,094 |
| Metoprolol Succinate | 199 | $2,993 |
| Carvedilol | 142 | $1,925 |
| Losartan Potassium | 106 | $1,138 |
| Furosemide | 104 | $987 |
| Spironolactone | 93 | $968 |
| Rosuvastatin Calcium | 52 | $793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndaqel, Eliquis | $6,004 | $386,07677 claims |
| Johnson & JohnsonXarelto | $16 | $175,708139 claims |
| NovartisEntresto | $177 | $100,59171 claims |
| AstraZenecaFarxiga, Brilinta | $329 | $35,00636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 101 cardiovascular disease providers in New Mexico.
Other cardiovascular disease in Albuquerque
- Abinash AchrekarAlbuquerque$88K
- Adam BanksAlbuquerque$38K
- Stacey CleggAlbuquerque$21K
- Leonardo MaciasAlbuquerque$15K
- Carolina Ponce OrellanaAlbuquerque$12K
- Warren LaskeyAlbuquerque$10K
- Kayvan ElliniAlbuquerque$10K
- Bilal AlqamAlbuquerque$8K
- Daniel FriedmanAlbuquerque$6K
- Robert TaylorAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.